393 related articles for article (PubMed ID: 10754313)
1. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
2. Engineered antibodies with increased activity to recruit complement.
Idusogie EE; Wong PY; Presta LG; Gazzano-Santoro H; Totpal K; Ultsch M; Mulkerrin MG
J Immunol; 2001 Feb; 166(4):2571-5. PubMed ID: 11160318
[TBL] [Abstract][Full Text] [Related]
3. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
4. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
5. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the effector functions of a human IgG1 through engineering of its hinge region.
Dall'Acqua WF; Cook KE; Damschroder MM; Woods RM; Wu H
J Immunol; 2006 Jul; 177(2):1129-38. PubMed ID: 16818770
[TBL] [Abstract][Full Text] [Related]
7. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
8. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
[TBL] [Abstract][Full Text] [Related]
9. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
10. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
11. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
12. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
13. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
Beers SA; Chan CH; James S; French RR; Attfield KE; Brennan CM; Ahuja A; Shlomchik MJ; Cragg MS; Glennie MJ
Blood; 2008 Nov; 112(10):4170-7. PubMed ID: 18583569
[TBL] [Abstract][Full Text] [Related]
14. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
Deveuve Q; Lajoie L; Barrault B; Thibault G
Front Immunol; 2020; 11():168. PubMed ID: 32117299
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
Tammen A; Derer S; Schwanbeck R; Rösner T; Kretschmer A; Beurskens FJ; Schuurman J; Parren PW; Valerius T
J Immunol; 2017 Feb; 198(4):1585-1594. PubMed ID: 28062698
[TBL] [Abstract][Full Text] [Related]
16. Atomic resolution model of the antibody Fc interaction with the complement C1q component.
Schneider S; Zacharias M
Mol Immunol; 2012 May; 51(1):66-72. PubMed ID: 22425350
[TBL] [Abstract][Full Text] [Related]
17. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
[TBL] [Abstract][Full Text] [Related]
18. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
19. Binding of the human complement subcomponent C1q to hybrid mouse monoclonal antibodies.
Koolwijk P; Boot JH; Griep R; Bast BJ
Mol Immunol; 1991 Jun; 28(6):567-76. PubMed ID: 1861677
[TBL] [Abstract][Full Text] [Related]
20. Structural characterization of a human Fc fragment engineered for lack of effector functions.
Oganesyan V; Gao C; Shirinian L; Wu H; Dall'Acqua WF
Acta Crystallogr D Biol Crystallogr; 2008 Jun; 64(Pt 6):700-4. PubMed ID: 18560159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
